CNC - Centene Corporation
After hours:
Chart Events
Momentum
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 63.43 |
| Open | 63.30 |
| Bid | 62.60 x 800 |
| Ask | 63.90 x 800 |
| Day's Range | 62.58 - 64.11 |
| 52 Week Range | 61.71 - 98.53 |
| Volume | |
| Avg. Volume | 3,412,135 |
| Market Cap | 34.419B |
| Beta (5Y Monthly) | 0.56 |
| PE Ratio (TTM) | 23.94 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
- Zacks
Centene (CNC) Down 3% Since Last Earnings Report: Can It Rebound?
Centene (CNC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
The Zacks Analyst Blog Highlights PepsiCo, Salesforce, Advanced Micro Devices, Centene and Gartner
PepsiCo, Salesforce, Advanced Micro Devices, Centene and Gartner are part of the Zacks top Analyst Blog.
- Zacks
Here's Why Hold Strategy is Apt for Centene (CNC) Stock Now
Centene's (CNC) health benefit ratio is estimated at 87.1-87.7% for 2023, signaling better operating efficiency.
- Simply Wall St.
Should Weakness in Centene Corporation's (NYSE:CNC) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Centene (NYSE:CNC) has had a rough three months with its share price down 5.3%. However, stock prices are usually...
- Zacks
Select Medical (SEM) Q1 Earnings Top on Improving Profitability
Select Medical (SEM) expects revenues to be within the range of $6.5-$6.7 billion in 2023, indicating a rise of 4.8% from the 2022 figure of $6.3 billion.
- Thomson Reuters StreetEvents
Q1 2023 Evolent Health Inc Earnings Call
Q1 2023 Evolent Health Inc Earnings Call
- Investopedia
10 Biggest Healthcare Companies
The healthcare sector includes companies that produce medical goods, such as drugs and medical devices, and companies that provide medical services, such as health insurance or hospital administration.
- Reuters
Centene to divest AI platform Apixio
The company, which acquired Apixio in December 2020, did not disclose the terms of the transaction. Apixio compiles and analyzes large volumes of unstructured patient data, including medical charts and physician's notes, into insights and curated data. "As part of our ongoing portfolio review, it was important for us to find a strategic partner for Apixio with whom the business can continue to grow," said Centene Chief Executive Office Sarah London said in a statement.
- Reuters
UPDATE 1-Centene to divest AI platform Apixio
Centene Corp will sell its artificial intelligence-powered healthcare analytics platform Apixio to investment firm New Mountain Capital as part of an ongoing portfolio review, the U.S. health insurer said on Wednesday. The company, which acquired Apixio in December 2020, did not disclose the terms of the transaction. Apixio compiles and analyzes large volumes of unstructured patient data, including medical charts and physician's notes, into insights and curated data.
- Zacks
Teladoc Health (TDOC) Shares Up 5% Since Q1 Earnings Release
Teladoc Health's (TDOC) Q1 results reflect solid chronic care product revenues and improving access fees and other revenues.
- Insider Monkey
Centene Corporation (NYSE:CNC) Q1 2023 Earnings Call Transcript
Centene Corporation (NYSE:CNC) Q1 2023 Earnings Call Transcript April 25, 2023 Centene Corporation beats earnings expectations. Reported EPS is $2.11, expectations were $2.09. Operator: Good day and welcome to the Centene Corporation First Quarter 2023 Earnings Conference Call. All participants will be in listen-only mode. After today’s presentation, there will be an opportunity to ask […]
- Motley Fool
Attention Value Investors: This Healthcare Stock Could Be a No-Brainer Buy
Picking leaders in massive industries with promising growth trends tends to work out well for investors over the long term. This is because operating as a leader in an industry set for growth makes it easier to increase revenue and earnings over time, which leads to stock price growth. An aging global population and the prevalence of sedentary lifestyles bode well for the health insurance industry.
- Zacks
Molina Healthcare (MOH) Beats on Q1 Earnings, Ups '23 EPS View
Molina Healthcare's (MOH) Q1 results reflect strong performance in the Medicaid and Medicare segments. Meanwhile, the elevated expense level partially offset the positives.
- Zacks
Universal Health (UHS) Q1 Earnings Beat on Higher Admissions
Universal Health's (UHS) Q1 results reflect strong performance in acute care and behavioral health segments. Meanwhile, the elevated expense level partially offsets the positives.
- Zacks
Humana (HUM) Q1 Earnings Beat on Growing Membership & Premiums
Humana (HUM) expects adjusted EPS to be at least $28.25 in 2023, up from the previous guidance of $28 per share.
- Zacks
Centene (CNC) Q1 Earnings Miss Estimates, '23 EPS View Raised
Centene's (CNC) first-quarter 2023 results grapple with higher operating expenses, partly offset by an expanding customer base. Management presently expects adjusted EPS to be at least $6.40 in 2023.
- Benzinga
Why Centene Stock Is Trading Higher Today
Centene Corp (NYSE: CNC) has reported a Q1 FY23 adjusted EPS of $2.11, compared to $1.83 a year ago, slightly beating the consensus of $2.10. Sales increased 4.58% Y/Y to $38.89 billion, beating the consensus of $35.95 billion. A health benefits ratio of 87% represents a decrease from 87.3% driven by continued disciplined Marketplace pricing and favorable Medicare performance. Managed care membership reached 28.45 million, +8.45% Y/Y. The cash flow provided by operations for the first quarter of
- Zacks
Centene (CNC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Centene (CNC) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- Zacks
Centene (CNC) Misses Q1 Earnings Estimates
Centene (CNC) delivered earnings and revenue surprises of -5.38% and 7.11%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- Reuters
UPDATE 4-Centene long-term forecast allays concerns over Medicare Advantage segment
Centene Corp on Tuesday maintained its long-term profit growth targets allaying investor concerns over a blow to its business from competition in the fast-growing Medicare Advantage segment, sending the health insurer's shares up 4%. Centene received a lower "Star Rating" for its Medicare Advantage health offerings in October, raising concerns that people could favour plans with better ratings as competition heats up in this space. Health insurers also face challenges to earnings in 2024 due to lower government payments for Medicare Advantage, while low-income people could shift out of Medicaid as COVID relief measures that had allowed them to remain on these plans are revoked.
- Reuters
Centene long-term forecast allays concerns over Medicare Advantage segment
(Reuters) -Centene Corp on Tuesday maintained its long-term profit growth targets allaying investor concerns over a blow to its business from competition in the fast-growing Medicare Advantage segment, sending the health insurer's shares up 4%. Centene received a lower "Star Rating" for its Medicare Advantage health offerings in October, raising concerns that people could favour plans with better ratings as competition heats up in this space. Health insurers also face challenges to earnings in 2024 due to lower government payments for Medicare Advantage, while low-income people could shift out of Medicaid as COVID relief measures that had allowed them to remain on these plans are revoked.
- Zacks
Will Lower Managed Care Profits Hurt Centene's (CNC) Q1 Earnings?
Centene's (CNC) first-quarter results are likely to reflect growth in premiums and lower costs.
- Motley Fool
Wall Street Thinks These 2 Value Stocks Could Soar
Many investing strategies can secure your financial future. The strategy that revolves around buying stocks for less than what they are worth is called value investing. Here are two large-cap stocks that Wall Street believes could be heading for a rebound in the year ahead.
- Simply Wall St.
Is Centene Corporation (NYSE:CNC) Trading At A 49% Discount?
Key Insights Centene's estimated fair value is US$136 based on 2 Stage Free Cash Flow to Equity Centene is estimated to...
